User profiles for SHIVAANI KUMMAR
Shivaani KummarProfessor of Medicine, OHSU Verified email at ohsu.edu Cited by 15141 |
[HTML][HTML] Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Background Fusions involving one of three tropomyosin receptor kinases (TRK) occur in
diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a …
diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a …
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
DS Hong, SG DuBois, S Kummar, AF Farago… - The Lancet …, 2020 - thelancet.com
Background The selective TRK inhibitor larotrectinib was approved for paediatric and adult
patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of …
patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of …
Nirogacestat, a γ-secretase inhibitor for desmoid tumors
…, T Philip, JG Pressey, S Kummar… - … England Journal of …, 2023 - Mass Medical Soc
Background Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors
without approved treatments. Methods We conducted a phase 3, international, double-blind, …
without approved treatments. Methods We conducted a phase 3, international, double-blind, …
[HTML][HTML] Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies
S Kummar, R Kinders, ME Gutierrez… - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
Purpose We conducted the first phase 0 clinical trial in oncology of a therapeutic agent
under the Exploratory Investigational New Drug Guidance of the US Food and Drug …
under the Exploratory Investigational New Drug Guidance of the US Food and Drug …
[HTML][HTML] Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors
Purpose Wee1 tyrosine kinase phosphorylates and inactivates cyclin-dependent kinase (Cdk)
1/2 in response to DNA damage. AZD1775 is a first-in-class inhibitor of Wee1 kinase with …
1/2 in response to DNA damage. AZD1775 is a first-in-class inhibitor of Wee1 kinase with …
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas
A phase I trial of ABT-888 (veliparib), a PARP inhibitor, in combination with topotecan, a
topoisomerase I–targeted agent, was carried out to determine maximum tolerated dose (MTD), …
topoisomerase I–targeted agent, was carried out to determine maximum tolerated dose (MTD), …
Wee1 kinase as a target for cancer therapy
K Do, JH Doroshow, S Kummar - Cell cycle, 2013 - Taylor & Francis
Wee1, a protein kinase, regulates the G 2 checkpoint in response to DNA damage. Preclinical
studies have elucidated the role of wee1 in DNA damage repair and the stabilization of …
studies have elucidated the role of wee1 in DNA damage repair and the stabilization of …
SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study
PD-1 inhibitors are approved for treating advanced melanoma, but resistance has been
observed. This phase Ib trial evaluated intratumoral SD-101, a synthetic CpG oligonucleotide …
observed. This phase Ib trial evaluated intratumoral SD-101, a synthetic CpG oligonucleotide …
Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer
This first-in-human study of an A2AR antagonist for cancer treatment establishes the safety
and feasibility of targeting this pathway by demonstrating antitumor activity with single-agent …
and feasibility of targeting this pathway by demonstrating antitumor activity with single-agent …
Compressing drug development timelines in oncology using phase'0'trials
S Kummar, R Kinders, L Rubinstein… - Nature Reviews …, 2007 - nature.com
The optimal evaluation of molecularly targeted anticancer agents requires the integration of
pharmacodynamic assays into early clinical investigations. Phase '0' trials conducted under …
pharmacodynamic assays into early clinical investigations. Phase '0' trials conducted under …